Allergic Bronchopulmonary Aspergillosis Clinical Trial
Official title:
iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of [68Ga]Ga-DFO-B PET/CT (gallium-68-deferoxamine) for the visualization of pulmonary Aspergillus infection. The incidence of fungal infections is on the rise and are associated with significant mortality. Diagnosis pulmonary aspergillosis can be can be challenging, often requiring invasive tests such as bronchoscopy and lung tissue biopsies. Molecular imaging, specifically using radiolabeled siderophores like [68Ga]Ga-DFO-B, offers a non-invasive and location-specific approach to visualize and evaluate infections. Siderophores, critical for pathogenic microbes like Aspergillus fumigatus, play a role in iron acquisition. Preclinical studies with radiolabeled deferoxamine (DFO-B) demonstrated distinct accumulation at infection sites. Additionally, [68Ga]Ga-DFO-B PET/CT may differentiate between Aspergillus infection and cancer, making it a promising non-invasive diagnostic tool for pulmonary aspergillosis.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01222273 -
Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
|
N/A | |
| Completed |
NCT04442269 -
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
|
Phase 2 | |
| Terminated |
NCT00787917 -
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
|
Phase 4 | |
| Completed |
NCT02273661 -
Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).
|
Phase 2 | |
| Not yet recruiting |
NCT05129033 -
A Prospective Study on Optimizing Treatment for ABPA
|
N/A | |
| Completed |
NCT02440009 -
A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
| Completed |
NCT01857479 -
A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00585364 -
Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA
|
N/A | |
| Completed |
NCT01621321 -
Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05444946 -
Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
|
N/A | |
| Terminated |
NCT03960606 -
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
|
Phase 2 | |
| Active, not recruiting |
NCT04227483 -
Deflazacort vs. Prednisolone in Acute-stage ABPA
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT05903612 -
Allergic Bronchopulmonary Aspergillosis Prescreening Study
|
||
| Completed |
NCT04229303 -
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
|
Phase 1 | |
| Completed |
NCT04476758 -
Immune Profiles in CF Fungal Infection
|
||
| Withdrawn |
NCT04108962 -
Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
|
Phase 4 | |
| Recruiting |
NCT06174922 -
A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
|
Phase 3 | |
| Completed |
NCT01321827 -
Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00974766 -
Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
| Completed |
NCT03059992 -
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
|
Phase 3 |